Key Highlights
- AbbVie Delivers $15.423 Billion in Q2 Revenues, Raising Full-Year Adjusted EPS Guidance to $11.88–$12.08
Strong performance in immunology and neuroscience underscores a diversified growth trajectory and continued market expansion. - Meaningful Pipeline Progress Fueled by Regulatory Approvals and Strategic Investments
Recent collaborations and licensing deals in external innovation highlight AbbVie’s commitment to maintaining an industry-leading development pipeline, with a growing focus on advanced RNA, cell therapy, and digital health technologies. - Sustained Growth Despite Humira Decline: Skyrizi, Rinvoq, and Neuroscience Portfolios Drive Double-Digit Gains
Sharp increases in Skyrizi (+62%), Rinvoq (+42%), and neuroscience therapies position AbbVie as an agile leader in high-value biologics and precision therapies for 2025.
Strong Q2 Financial Performance and Guidance Raise
AbbVie reported Q2 2025 net revenues of $15.423 billion, up 6.6% year-over-year, with adjusted diluted EPS rising 12% to $2.97 per share despite a $0.42 per share impact from IPR&D and milestone expenses. The company’s immunology and neuroscience franchises remain key growth engines as Humira biosimilar headwinds are offset by rapid expansion in products such as Skyrizi and Rinvoq.
Pipeline Progress and Regulatory Momentum
Recent FDA approvals—such as Rinvoq for giant cell arteritis and Emrelis for metastatic NSCLC—cap another quarter of significant regulatory and clinical wins. New data from pivotal trials in alopecia areata and migraine further demonstrate AbbVie’s R&D productivity and progress toward addressing unmet needs in multiple therapeutic areas.
Strategic External Innovation and Next-Gen Therapies
AbbVie’s focus on external innovation is reflected in recent collaborations and licensing agreements—most notably with Capstan Therapeutics for in vivo CAR-T RNA delivery and with ADARx Pharmaceuticals for next-generation siRNA platforms. These partnerships bolster AbbVie’s position at the intersection of biologics, RNA, and emerging AI-driven drug development technologies.
Diversified Growth Across Portfolios and Geographies
While U.S. Humira sales contracted, global immunology advanced by 9.5%, neuroscience jumped 24%, and key neurology brands like Vraylar and Botox Therapeutic delivered double-digit growth. The oncology portfolio remains robust, with Venclexta and Elahere revenue growth and continued investment in antibody-drug conjugates and cell therapies.
About AbbVie
AbbVie (NYSE: ABBV) is a global biopharmaceutical company focused on discovering and delivering transformative medicines across immunology, oncology, neuroscience, eye care, and aesthetics. For more, visit www.abbvie.com or access the AbbVie News Center.
By